Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Dakota Vafseo Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield – South DakotaPolicy 05.05.54

    Vafseo (vadadustat) Coverage

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.05.54 alerts

    Get alerted when Policy 05.05.54 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization coverage of Vafseo for adults with anemia due to chronic kidney disease who have received dialysis for at least three months. Coverage requires fulfillment of the applicable initial or continuation criteria, documentation, prescriber qualifications, and dosing limits.

    Policy Summary
    PayerBlue Cross Blue Shield – South Dakota
    PolicyVafseo (vadadustat) Coverage
    Policy CodePolicy 05.05.54
    Change TypeNo material change
    Effective DateDec 19, 2025
    Last ReviewOct 1, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization documentation of the diagnosis, dialysis duration, laboratory values, prior ESA treatment and response, and applicable approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    24 weeksInitial and continuation authorization period
    ≥3 monthsMinimum dialysis duration for coverage

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    <11 g/dLRequired pretreatment hemoglobin threshold
    600 mg/dayMaximum dose referenced in continuation criteria
    30 tablets/30 daysStandard quantity limit for 150 mg tablets

    Vafseo Coverage Criteria

    Initial Therapy

    Covered for an initial authorization of 24 weeks when ALL of the following criteria are met:

    ALL of the following

    • Member is 18 years of age or older
    • Member has been receiving dialysis for at least 3 months≥ 3 months
    • Member has a diagnosis of anemia due to chronic kidney disease (CKD)
    • ONE of

      • Member has been assessed for iron deficiency anemia and has adequate iron stores
      • Member is receiving iron supplementation prior to starting therapy with Vafseo
    • Member has a pretreatment hemoglobin level below 11 g/dL, excluding values reflecting a recent transfusion< 11 g/dL
    • ONE of

      • Member is requiring more than 300 IU/kg per week of epoetin alfa (e.g., Epogen, Procrit, Retacrit)> 300 IU/kg/week
      • Member is requiring at least 1.5 mcg/kg per week of darbepoetin alfa (Aranesp)≥ 1.5 mcg/kg/week
    • Member does NOT meet any of the following exclusion criteria

      • No cardiovascular abnormality (e.g., myocardial infarction, acute coronary syndrome, stroke, or transient ischemic attack) within 4 weeks of initiation of therapy with Vafseo
      • No uncontrolled hypertension, defined as predialysis systolic blood pressure above 190 mmHg or diastolic blood pressure above 110 mmHg at rest≤ 190/110 mmHg
      • No history of New York Heart Association (NYHA) Class IV heart failure, and no liver disease (e.g., ALT above 2 times the upper limit of normal, bilirubin above 1.5 times the upper limit of normal, current unstable liver disease, or biliary disease)
      • No history of malignancy within 2 years of initiation of therapy with Vafseo; member is not currently receiving cancer treatment; and member has no history of a complex kidney cyst
      • No planned receipt of a living kidney transplant

    Continuation Therapy

    Covered for a continuation authorization of 24 weeks when ALL of the following criteria are met:

    ALL of the following

    • ONE of

      • Member has achieved or maintained a clinically meaningful increase in hemoglobin of at least 1 g/dL from baseline and the hemoglobin level is no higher than 11 g/dL≥ 1 g/dL increase; ≤ 11 g/dL
      • ALL of the following

        • Member has not achieved or maintained a clinically meaningful increase in hemoglobin of at least 1 g/dL from baseline
        • Member's dose will be increased as tolerated to a maximum of 600 mg per day≤ 600 mg/day

    Vafseo (vadadustat) has not been shown to improve quality of life, fatigue, or patient well-being. It is not indicated as a substitute for transfusion in patients requiring immediate correction of anemia or for patients with anemia due to CKD who are not on dialysis.

    Initial approval is excluded for members with the cardiovascular, uncontrolled hypertension, NYHA Class IV heart failure, liver disease, recent malignancy or active cancer treatment, complex kidney cyst, or planned living kidney transplant conditions specified in the Initial Therapy criteria above.

    Vafseo must not be used concurrently with an erythropoiesis-stimulating agent (ESA), including epoetin alfa (Epogen, Procrit, Retacrit), darbepoetin alfa (Aranesp), or methoxy polyethylene glycol-epoetin beta (Mircera). This restriction applies to both initial and continuation therapy.

    Vafseo (vadadustat) is considered not medically necessary for members who do not meet the criteria set forth above.

    Billing Codes and Clinical Thresholds

    HCPCSHCPCS
    J0901Vadadustat, oral, 1 mg (for esrd on dialysis) (effective 1/1/2025)
    Unclassified drug or biologic codesHCPCS
    J3490Unclassified drugs (when specified as [Vafseo])
    C9399Unclassified drugs or biologics (when specified as [Vafseo])
    Minimum age
    Minimum age18 years or older
    Dialysis duration
    Dialysis durationAt least 3 months
    Pretreatment hemoglobin
    Pretreatment hemoglobinBelow 11 g/dL, excluding values reflecting recent transfusion
    Epoetin alfa hyporesponsiveness

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Vafseo (vadadustat). Submit the documentation needed for both initial and continuation requests so the plan can evaluate the applicable coverage criteria.

    • Initial requests: chart notes, medical records, laboratory values, diagnosis and dialysis history, prior ESA treatment and response.
    • Continuation requests: recent hemoglobin values, excluding values reflecting recent transfusion.
    • Authorization is issued for 24 weeks when the applicable criteria are met.
    Denial Risk

    ESA Hyporesponsiveness Required

    Initial approval requires documented hyporesponsiveness to an erythropoiesis-stimulating agent (ESA). The member must meet at least one of the specified ESA dose thresholds.

    Clinical Background

    Anemia of chronic kidney disease becomes more common as CKD advances because diseased kidneys produce inadequate amounts of erythropoietin. Vafseo (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor indicated for anemia due to CKD in adults receiving dialysis for at least 3 months. The policy describes Vafseo as an alternative for patients who are hyporesponsive or intolerant to ESAs and notes boxed-warning risks including death, myocardial infarction, stroke, venous thromboembolism, and vascular-access thrombosis.

    NYHA Functional Classification

    NYHA Class I
    Functional limitationNo limitation of physical activity; ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea
    NYHA Class II
    Functional limitationSlight limitation of physical activity; comfortable at rest, but ordinary physical activity causes fatigue, palpitation, or dyspnea
    NYHA Class III
    Functional limitationMarked limitation of physical activity; comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea
    NYHA Class IV

    Initial Authorization Criteria

    Initial Therapy Criteria

    Authorization of 24 weeks may be granted when all initial approval criteria are met.

    Initial approval

    • Clinical eligibility

      • Required eligibility

        • Member is 18 years of age or older and has been receiving dialysis for at least 3 months.Age ≥18 years; dialysis ≥3 months
        • Member has a diagnosis of anemia due to chronic kidney disease (CKD).
        • Iron status

    Continuation Authorization Criteria

    Continuation Therapy Criteria

    Authorization of 24 weeks may be granted when the continuation criteria are met.

    Continuation therapy

    • Hemoglobin response pathway

      • Meaningful response

        • Member has achieved or maintained a clinically meaningful increase in hemoglobin of at least 1 g/dL from baseline, and the member's hemoglobin level is ≤11 g/dL.Hemoglobin increase ≥1 g/dL from baseline; hemoglobin ≤11 g/dL
      • No meaningful response with dose optimization

        • The member's dose will be increased as tolerated to a maximum of 600 mg per day.Maximum 600 mg/day

    Required Prior Therapy

    StepRequirementDocumentation threshold
    1Member must be hyporesponsive to an erythropoiesis-stimulating agent before initial Vafseo approval.Epoetin alfa: >300 IU/kg per week, or darbepoetin alfa: ≥1.5 mcg/kg per week.

    Pharmacy Quantity Limits

    Vafseo (vadadustat)
    Standard quantity limit30 tablets
    Vafseo (vadadustat) 150 mg tablet
    Standard quantity limit30 tablets per 30 days
    Vafseo (vadadustat) 300 mg tablet
    Standard quantity limit60 tablets per 30 days
    Policy Summary
    PayerBlue Cross Blue Shield – South Dakota
    PolicyVafseo (vadadustat) Coverage
    Policy CodePolicy 05.05.54
    Change TypeNo material change
    Effective DateDec 19, 2025
    Last ReviewOct 1, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization documentation of the diagnosis, dialysis duration, laboratory values, prior ESA treatment and response, and applicable approval criteria.
    SourceLink
    On This Page
    Vafseo Coverage CriteriaBilling Codes and Clinical ThresholdsAuthorization and Documentation RequirementsClinical BackgroundNYHA Functional ClassificationInitial Authorization CriteriaContinuation Authorization CriteriaRequired Prior TherapyPharmacy Quantity Limits
    Member has NOT received 600 mg per day for more than 24 weeks without achieving a clinically meaningful increase in hemoglobin of at least 1 g/dL
  1. Member's hemoglobin is no higher than 11 g/dL≤ 11 g/dL
  2. ONE of

    • Member has been assessed for iron deficiency anemia and has adequate iron stores
    • Member is receiving iron supplementation before continuing therapy with Vafseo
  3. Epoetin alfa hyporesponsiveness
    More than 300 IU/kg per week
    Darbepoetin alfa hyporesponsiveness
    Darbepoetin alfa hyporesponsivenessAt least 1.5 mcg/kg per week
    Uncontrolled hypertension
    Uncontrolled hypertensionPredialysis systolic blood pressure above 190 mmHg or diastolic blood pressure above 110 mmHg at rest
    Recent cardiovascular abnormality
    Recent cardiovascular abnormalityWithin four weeks of initiation of therapy
    Liver laboratory exclusion
    Liver laboratory exclusionALT above 2 times ULN or bilirubin above 1.5 times ULN
    Clinically meaningful hemoglobin response
    Clinically meaningful hemoglobin responseIncrease of at least 1 g/dL from baseline
    Continuation hemoglobin threshold
    Continuation hemoglobin threshold11 g/dL or lower
    Maximum dose
    Maximum dose600 mg per day
    Maximum-dose response period
    Maximum-dose response periodDo not receive 600 mg per day for more than 24 weeks without a clinically meaningful hemoglobin increase of at least 1 g/dL
  4. Epoetin alfa requirement: >300 IU/kg per week.
  5. Darbepoetin alfa requirement: ≥1.5 mcg/kg per week.
  6. Relevant ESAs include epoetin alfa (Epogen, Procrit, Retacrit), darbepoetin alfa (Aranesp), and methoxy polyethylene glycol-epoetin beta (Mircera).
  7. Documentation Required

    Required Clinical Documentation

    Provide complete clinical documentation to support the request and demonstrate that the coverage criteria are met.

    • Chart notes and medical record documentation.
    • Laboratory values, including hemoglobin, ferritin, and transferrin saturation.
    • Diagnosis of anemia due to CKD and duration of dialysis.
    • Prior ESA treatment details, including dose, frequency, duration, and response.
    • For continuation requests, recent hemoglobin values excluding values reflecting recent transfusion.
    Note

    Qualified Prescriber or Consultant

    Vafseo must be prescribed by, or prescribed in consultation with, a qualified specialist.

    • Nephrologist
    • Hematologist
    Denial Risk

    Use Within Labeled Limitations

    Use Vafseo consistently with its labeled limitations. Coverage is not supported for uses outside the covered dialysis-dependent CKD anemia population or when immediate correction of anemia is required.

    • Not indicated for anemia due to CKD in patients who are not on dialysis.
    • Not indicated as a substitute for transfusion in patients requiring immediate correction of anemia.
    • Has not been shown to improve quality of life, fatigue, or patient well-being.
    Denial Risk

    Initial Criteria Not Met

    Initial authorization may be denied when the member does not meet the required eligibility, diagnosis, laboratory, treatment, or safety criteria.

    • Member is younger than 18 years of age or has received dialysis for less than 3 months.
    • No diagnosis of anemia due to CKD.
    • Iron deficiency anemia has not been assessed, iron stores are inadequate, and the member is not receiving iron supplementation before therapy.
    • Pretreatment hemoglobin is ≥11 g/dL, excluding values reflecting recent transfusion.
    • Member is not hyporesponsive to an ESA at the required dose threshold.
    • Requested drug will be used with an ESA.
    • Member has a cardiovascular abnormality within 4 weeks of initiation, uncontrolled hypertension (predialysis systolic BP >190 mmHg or diastolic BP >110 mmHg at rest), NYHA Class IV heart failure, specified liver or biliary disease, recent malignancy or active cancer treatment, a complex kidney cyst, or a planned living kidney transplant.
    Denial Risk

    Continuation Criteria Not Met

    Continuation authorization may be denied when the member does not meet the hemoglobin response, iron-status, dosing, or concomitant-therapy requirements.

    • Hemoglobin has increased or been maintained by ≥1 g/dL from baseline but is >11 g/dL.
    • If a clinically meaningful hemoglobin increase of ≥1 g/dL has not been achieved or maintained, the dose will not be increased as tolerated to a maximum of 600 mg per day.
    • The member has received 600 mg per day for >24 weeks without achieving a clinically meaningful hemoglobin increase of ≥1 g/dL.
    • Hemoglobin is >11 g/dL when the alternative continuation pathway applies.
    • Iron deficiency anemia has not been assessed, iron stores are inadequate, and the member is not receiving iron supplementation before continuation.
    • Requested drug will be used with an ESA.
    • Continuation authorization is limited to 24 weeks when criteria are met.
    Denial Risk

    Not Medically Necessary

    Vafseo is considered not medically necessary when the member does not meet the coverage criteria set forth in this policy.

    • Requests that fail the applicable initial or continuation criteria may be denied as not medically necessary.
    Functional limitationUnable to carry on any physical activity without discomfort; heart failure symptoms are present at rest and discomfort increases with activity
    Member has adequate iron stores.
  8. Member is receiving iron supplementation before starting therapy with Vafseo.
  9. Hemoglobin and ESA hyporesponsiveness

    • Member has a pretreatment hemoglobin level less than 11 g/dL, excluding values reflecting a recent transfusion.Hemoglobin <11 g/dL
    • ESA hyporesponsiveness

      • Member requires more than 300 IU/kg per week of epoetin alfa.Epoetin alfa >300 IU/kg/week
      • Member requires at least 1.5 mcg/kg per week of darbepoetin alfa.Darbepoetin alfa ≥1.5 mcg/kg/week
  10. No exclusionary condition

    • Member does not have a cardiovascular abnormality, including myocardial infarction, acute coronary syndrome, stroke, or transient ischemic attack, within 4 weeks of initiation of therapy.No cardiovascular abnormality within 4 weeks of initiation
    • Member does not have uncontrolled hypertension.Predialysis systolic blood pressure must not be >190 mmHg or diastolic blood pressure >110 mmHg at rest
    • Member does not have a history of NYHA Class IV heart failure or liver disease, including ALT >2x ULN, bilirubin >1.5x ULN, current unstable liver disease, or biliary disease.ALT must not be >2x ULN; bilirubin must not be >1.5x ULN
    • Member does not have a history of malignancy within 2 years of initiation, is not currently receiving cancer treatment, and does not have a history of a complex kidney cyst.
    • Member is not planning to receive a living kidney transplant.
  11. Concomitant therapy

    • Member will not use Vafseo with an erythropoiesis-stimulating agent (ESA).
  12. The member has not received 600 mg per day for more than 24 weeks without achieving a clinically meaningful increase in hemoglobin of at least 1 g/dL.Not >24 weeks at 600 mg/day without hemoglobin increase ≥1 g/dL
  13. Member's hemoglobin level is ≤11 g/dL.Hemoglobin ≤11 g/dL
  14. Iron status

    • Member has adequate iron stores.
    • Member is receiving iron supplementation before continuing therapy with Vafseo.
  15. Concomitant therapy

    • Member will not use Vafseo with an erythropoiesis-stimulating agent (ESA).